Targeting changes in mitochondria to overcome drug resistance in acute myeloid leukemia
Targeting mitochondrial dynamics in drug-resistant acute myeloid leukemia
['FUNDING_OTHER'] · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · NIH-11035199
This study is looking at how changes in tiny parts of your cells called mitochondria might make it harder for some people with acute myeloid leukemia to respond to a common treatment, and it hopes to find new ways to improve those treatments for patients who are struggling.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUTGERS BIOMEDICAL AND HEALTH SCIENCES (nih funded) |
| Locations | 1 site (Newark, UNITED STATES) |
| Trial ID | NIH-11035199 on ClinicalTrials.gov |
What this research studies
This research investigates how changes in mitochondrial structure and function contribute to drug resistance in acute myeloid leukemia (AML). It focuses on the role of specific genes that affect mitochondrial dynamics, particularly in patients who have developed resistance to the drug venetoclax. By using advanced techniques like CRISPR, the study aims to identify potential new treatment strategies that could enhance the effectiveness of existing therapies. Patients may benefit from a deeper understanding of their disease and potentially new therapeutic options that target these mitochondrial changes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia who have developed resistance to venetoclax.
Not a fit: Patients with acute myeloid leukemia who have not been treated with venetoclax or those with other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with drug-resistant acute myeloid leukemia.
How similar studies have performed: Other research has shown promising results in targeting mitochondrial dynamics in cancer treatment, suggesting that this approach may be effective.
Where this research is happening
Newark, UNITED STATES
- RUTGERS BIOMEDICAL AND HEALTH SCIENCES — Newark, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GLYTSOU, CHRISTINA — RUTGERS BIOMEDICAL AND HEALTH SCIENCES
- Study coordinator: GLYTSOU, CHRISTINA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.